CEMI - Chembio Diagnostics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.0000
-0.0700 (-1.72%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.0700
Open4.0712
Bid4.0000 x 1000
Ask4.0400 x 46000
Day's Range3.9500 - 4.1300
52 Week Range3.8000 - 7.9000
Volume33,955
Avg. Volume57,903
Market Cap70.877M
Beta (3Y Monthly)1.68
PE Ratio (TTM)N/A
EPS (TTM)-0.7800
Earnings DateNov 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.25
  • Should You Avoid Chembio Diagnostics Inc (CEMI) Too?
    Insider Monkey

    Should You Avoid Chembio Diagnostics Inc (CEMI) Too?

    Before we spend days researching a stock idea we like to take a look at how hedge funds and billionaire investors recently traded that stock. Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018. This means hedge funds […]

  • Thomson Reuters StreetEvents

    Edited Transcript of CEMI earnings conference call or presentation 7-Nov-19 9:30pm GMT

    Q3 2019 Chembio Diagnostics Inc Earnings Call

  • GlobeNewswire

    Chembio Diagnostics Completes Acquisition of Orangelife

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has completed its previously announced acquisition of Orangelife Comercio e Industria Ltda., a Brazilian manufacturer and distributor of point-of-care diagnostics tests for infectious diseases. “Our acquisition of Orangelife strategically broadens our commercialization by enhancing our presence in Brazil, which we view as one of the most attractive infectious disease testing markets in the world,” said John Sperzel, Chembio’s Chief Executive Officer. Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases.

  • GlobeNewswire

    Chembio Diagnostics to Participate in Upcoming Investor Conferences

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today the company plans to participate in two upcoming investor conferences. Management is scheduled to present at the Canaccord Genuity MedTech & Diagnostics Forum in New York, New York on Thursday, November 21, 2019 at 3:00 pm ET.

  • Imagine Owning Chembio Diagnostics (NASDAQ:CEMI) And Wondering If The 35% Share Price Slide Is Justified
    Simply Wall St.

    Imagine Owning Chembio Diagnostics (NASDAQ:CEMI) And Wondering If The 35% Share Price Slide Is Justified

    In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

  • GlobeNewswire

    Chembio Diagnostics Reports Third Quarter 2019 Financial Results

    MEDFORD, N.Y., Nov. 07, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial.

  • GlobeNewswire

    Chembio Diagnostics Enters into Definitive Agreement to Acquire Orangelife

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has entered into a definitive agreement (the “Agreement”) to acquire Orangelife Comercio e Industria Ltda., a privately-held Brazilian manufacturer and distributor of point-of-care diagnostics tests for infectious diseases. Under the terms of the Agreement, Chembio will make an upfront payment of $150,000 in cash and 153,707 shares of common stock. The Agreement contemplates that Chembio will also enter into certain consulting agreements that could include payment of up to 497,288 additional shares of common stock based on the achievement of certain sales and regulatory milestones between 2020 and 2022.

  • GlobeNewswire

    Chembio Diagnostics Receives WHO Prequalification Approval for HIV Self-Test

    November 4, 2019 - Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced its SURE CHECK HIV Self-Test has received World Health Organization (WHO) Prequalification approval. The WHO Prequalification of In Vitro Diagnostics (IVD) is a comprehensive assessment of individual IVDs through a standardized process that includes inspection of the manufacturing site, review of a product dossier, performance evaluation including operational characteristics, and labelling review.

  • GlobeNewswire

    Chembio Diagnostics to Report Third Quarter 2019 Financial Results on November 7, 2019

    MEDFORD, NY, Oct. 24, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will.

  • GlobeNewswire

    Chembio Diagnostics Receives WHO Prequalification Approval for Malaysia Facility

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced its manufacturing facility in Malaysia has been qualified by the World Health Organization (WHO) Prequalification program to produce Stat-Pak HIV 1/2 tests. The WHO Prequalification of In Vitro Diagnostics (IVD) is a comprehensive assessment of individual IVDs through a standardized assessment process that includes inspection of the manufacturing site, review of a product dossier, performance evaluation including operational characteristics, and labelling review.

  • Is Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) CEO Salary Justified?
    Simply Wall St.

    Is Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) CEO Salary Justified?

    John Sperzel has been the CEO of Chembio Diagnostics, Inc. (NASDAQ:CEMI) since 2014. This report will, first, examine...

  • Chembio Diagnostics (NASDAQ:CEMI) Has Debt But No Earnings; Should You Worry?
    Simply Wall St.

    Chembio Diagnostics (NASDAQ:CEMI) Has Debt But No Earnings; Should You Worry?

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • GlobeNewswire

    Chembio Diagnostics Announces $20 Million Term Loan with Perceptive Advisors

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the closing of a $20 million term loan with an affiliate of Perceptive Advisors, one of the world’s leading healthcare-focused investment firms. “We are excited to have received this capital from Perceptive Advisors, a prestigious and well-regarded healthcare investment firm.” said John Sperzel, Chembio’s Chief Executive Officer.

  • Thomson Reuters StreetEvents

    Edited Transcript of CEMI earnings conference call or presentation 6-Aug-19 8:30pm GMT

    Q2 2019 Chembio Diagnostics Inc Earnings Call

  • What Kind Of Shareholder Owns Most Chembio Diagnostics, Inc. (NASDAQ:CEMI) Stock?
    Simply Wall St.

    What Kind Of Shareholder Owns Most Chembio Diagnostics, Inc. (NASDAQ:CEMI) Stock?

    The big shareholder groups in Chembio Diagnostics, Inc. (NASDAQ:CEMI) have power over the company. Large companies...

  • GlobeNewswire

    Chembio Diagnostics Reports Second Quarter 2019 Financial Results

    MEDFORD, N.Y., Aug. 06, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial.

  • GlobeNewswire

    Chembio Diagnostics to Participate in the Canaccord Genuity Growth Conference

    MEDFORD, N.Y., July 24, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today the.

  • GlobeNewswire

    Chembio Diagnostics to Report Second Quarter 2019 Financial Results on August 6, 2019

    MEDFORD, N.Y., July 24, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it.

  • GlobeNewswire

    Chembio Diagnostics and Takeda Pharmaceutical Company Enter Collaboration to Develop Point-of-Care Diagnostic Test

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care (POC) diagnostics company focused on infectious diseases, today announced that it has entered into a collaboration with Shire Human Genetic Therapies, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, a global pharmaceutical company, to develop a novel POC diagnostic test to detect an undisclosed biomarker. Under terms of the agreement, Chembio will receive funding from Takeda, subject to satisfying certain milestones, to develop a quantitative POC test utilizing Chembio’s patented DPP platform and hand-held optical analyzer. The development of the POC test will build upon Takeda’s technical research on a unique set of biomarkers and is expected to provide quantitative results in approximately 15 minutes from a small 10µL drop of fingerstick blood.

  • Should You Be Concerned About Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) Historical Volatility?
    Simply Wall St.

    Should You Be Concerned About Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) Historical Volatility?

    Anyone researching Chembio Diagnostics, Inc. (NASDAQ:CEMI) might want to consider the historical volatility of the...

  • GlobeNewswire

    Chembio Diagnostics Receives CE Mark for its Point-of-Care Multiplex Test for Zika, Dengue and Chikungunya

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that is has obtained a CE mark for its DPP Zika/Dengue/Chikungunya multiplex test system. Chembio’s DPP Zika/Dengue/Chikungunya multiplex test allows simultaneous and discrete detection of antibodies for both active (IgM) and prior exposure (IgG) to the Zika, dengue, and chikungunya viruses, which is important for both treatment and surveillance. The test is performed using a small (10µL) drop of fingertip blood and provides quantitative results in approximately 15 minutes when used with the company’s handheld DPP Micro Reader.

  • GlobeNewswire

    Chembio Diagnostics Announces Approval of Dengue Point-of-Care Test by Brazil’s Health Regulatory Agency

    Chembio Diagnostics, Inc. (CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the approval of its DPP Dengue System by Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s health regulatory agency, in collaboration with Bio-Manguinhos, a Brazilian government agency and supplier of diagnostic products to Brazil’s Ministry of Health. Chembio’s DPP Dengue test allows simultaneous and discrete detection of antibodies against all four dengue serotypes for both active infection by dengue virus (IgM) and prior exposure to the dengue virus (IgG), which is important for both treatment and surveillance.

  • Thomson Reuters StreetEvents

    Edited Transcript of CEMI earnings conference call or presentation 1-May-19 8:30pm GMT

    Q1 2019 Chembio Diagnostics Inc Earnings Call

  • GlobeNewswire

    Chembio Diagnostics Reports First Quarter 2019 Financial Results

    MEDFORD, N.Y., May 01, 2019 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial.